The FDA announced on April 15, 2026 that it will convene a panel of outside advisers in July 2026 to review whether seven peptides, including BPC-157, should be added to a list of substances that compounding pharmacies can safely produce. Health Secretary Robert F. Kennedy Jr., who has publicly discussed using peptides for his own injuries and previewed the announcement on Joe Rogan's podcast, has repeatedly pledged to loosen peptide regulations despite the FDA's 2023 restrictions citing safety risks including cancer and organ damage. The review comes after the Biden administration added nearly 20 peptides to the restricted substances list and FDA advisers voted overwhelmingly that peptides did not meet safety criteria for compounding, though many of those advisers no longer work at the agency. Critics including former FDA official Dr. Peter Lurie warn that allowing untested peptides threatens the FDA's drug approval system, while the compounding industry argues restrictions have created dangerous illicit markets for imported chemicals from China.
Story comments
Loading comments…